Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PASSAGE BIO INC.
PASG | US
5.84
USD-0.06
-1.02%
PASG | US
Loading StockChartView...
About PASSAGE BIO INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
5.84
Open
5.87
High
6.00
Low
5.73
Passage Bio Inc. a genetic medicines company develops transformative therapies for central nervous system diseases. It develops PBGM01 a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02 a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03 a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement and a development services and clinical supply agreement with Catalent Maryland Inc. The company was incorporated in 2017 and is headquartered in Philadelphia Pennsylvania.
View LessPASG | US
Risk
219.9
Sharpe
-0.14
Luna's Score
36/100
Recommendation
Sell
Luna says (PASG | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
240.0%1 month
219.9%3 months
143.5%6 months
139.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.41
Debt to equity
0.29
Debt to assets
0.21
Ent. to EBITDA
0.87
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-84.65M
MarketCap
360.72M
MarketCap(USD)
360.72M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-63.55
Short ratio
6.28
Short perc.
3.30
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
6.27
Range1M
6.27
Range3M
7.61
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.47
Price X volume
325.86K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.87 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.41 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 143.45 | 72.80 | Riskier |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.21 | 0.25 | Par |
| Market Cap | 360.72M | 3.66B | Emerging |
